One of the partners of the Marseille Immunopôle cluster is an immuno-technology center focused on translational research called MI-mAbs (“MI” for Marseille Immunopole, and “mAbs” for monoclonal antibodies).
It aims to bridge the gap between industry and academia by accelerating the development of novel monoclonal antibodies for new targets.
MI-mAbs is based in the Parc Scientifique et Technologie de Luminy.
It’s a stone’s throw from the Centre d’Immunologie de Marseille-Luminy (CIML), which this year celebrated its 40th anniversary (1976-2016).
Luminy is also the home to several companies focused on immuno-oncology, including Innate Pharma and HalioDx. Marseille has the ambition to become a world leader in the development of immune-based therapies
MI-mAbs is funded by a €19M award from the French Government, as part of their Investissments d’avenir/Investments for the Future program.
The Scientific Director of MI-mAbs is Professor François Romagné. He’s a co-founder of Innate Pharma and for 14 years was the company’s Chief Scientific Officer (CSO). He’s one of the inventors of lirilumab and monalizumab, both of which are in phase 2 clinical trials.
Professor Romagné kindly spoke to BSB about MI-mAbs and how it plans to accelerate innovation and develop new drug candidates for the treatment of cancer or inflammatory disease.
For our French speaking audience, here is a brief excerpt from the interview with Pr. Romagné, where he introduces himself and MI-mAbs.
It’s an incredible time for immunologists like Prof Romagné, where the clinical results we are seeing with new cancer immunotherapies have validated a lifetime of work.